MedTrace Logo

Neoadjuvant AXITINIB and AVELUMAB for Patients With Localized Clear-cell RCC

NCT03341845 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2018-05-21

No results posted yet for this study

Summary

a monocenter, open label, single arm, phase II study of the combination of axitinib with avelumab as neoadjuvant therapy in patients with intermediate to high-risk non-metastatic RCC.

Conditions

Interventions

DRUG

Axitinib

axitinib in combination with avelumab

DRUG

Avelumab

axitinib in combination with avelumab

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • The Netherlands Cancer Institute

    lead OTHER

Principal Investigators

  • Axel Bex, MD · NKI-AvL

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-28
Primary Completion
2023-01-31
Completion
2025-01-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03341845 on ClinicalTrials.gov